Compare US Bancorp (USB) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Bancorp vs Zoetis Inc — how do they compare? US Bancorp trades at $63.7 (market cap $98.36B), while Zoetis Inc trades at $75.53 (market cap $31.95B). The key difference: US Bancorp is far larger — about 3.1× Zoetis Inc's market cap, and US Bancorp pays the higher dividend (3.29%). Which is the better fit depends on your goals.
| USB | ZTS | |
|---|---|---|
Market Cap | $98.36B | $31.95B |
Sector | Financials | Health |
52-Week High | $64.01 | $156.76 |
52-Week Low | $43.94 | $71.91 |
Dividend Yield | 3.29% | 2.78% |
Enterprise Value | — | $39.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
U.S. Bancorp (USB) trades at $63.71, up 0.9% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with three consecutive quarterly EPS beats, a P/E of 12.6, and a net income margin of 27.61%. Recent Q2 2026 results highlighted record revenue driven by loan growth and fee income, with the company raising its full-year revenue outlook to 7%-9% growth. Analyst consensus is a Buy with a $70.17 price target, indicating 10% upside potential.
The outlook for USB is positive, supported by earnings momentum, dividend yield near 3%, and institutional optimism. Key risks include rising debt-to-asset ratios, potential credit quality deterioration, and macroeconomic sensitivity. Investors should weigh the stock's attractive valuation against sector-wide interest rate and regulatory uncertainties for balanced exposure.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
